PT2069336E - Derivados de piridin-4-ilo como agentes imunomoduladores - Google Patents
Derivados de piridin-4-ilo como agentes imunomoduladoresInfo
- Publication number
- PT2069336E PT2069336E PT78262870T PT07826287T PT2069336E PT 2069336 E PT2069336 E PT 2069336E PT 78262870 T PT78262870 T PT 78262870T PT 07826287 T PT07826287 T PT 07826287T PT 2069336 E PT2069336 E PT 2069336E
- Authority
- PT
- Portugal
- Prior art keywords
- pyridin
- derivatives
- immunomodulating agents
- immunomodulating
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2006053147 | 2006-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2069336E true PT2069336E (pt) | 2013-03-07 |
Family
ID=38983600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT78262870T PT2069336E (pt) | 2006-09-07 | 2007-09-06 | Derivados de piridin-4-ilo como agentes imunomoduladores |
Country Status (27)
Country | Link |
---|---|
US (1) | US8580824B2 (pt) |
EP (1) | EP2069336B1 (pt) |
JP (1) | JP5253401B2 (pt) |
KR (1) | KR101470659B1 (pt) |
CN (1) | CN101511827B (pt) |
AR (1) | AR062683A1 (pt) |
AU (1) | AU2007292993B2 (pt) |
BR (1) | BRPI0716171B8 (pt) |
CA (1) | CA2661105C (pt) |
CL (1) | CL2007002593A1 (pt) |
CY (1) | CY1113727T1 (pt) |
DK (1) | DK2069336T3 (pt) |
ES (1) | ES2400533T3 (pt) |
HK (1) | HK1133654A1 (pt) |
HR (1) | HRP20130181T1 (pt) |
IL (1) | IL197393A (pt) |
MA (1) | MA30718B1 (pt) |
MX (1) | MX2009002233A (pt) |
MY (1) | MY149853A (pt) |
NO (1) | NO342156B1 (pt) |
NZ (1) | NZ576060A (pt) |
PL (1) | PL2069336T3 (pt) |
PT (1) | PT2069336E (pt) |
RU (1) | RU2447071C2 (pt) |
SI (1) | SI2069336T1 (pt) |
TW (1) | TWI392671B (pt) |
WO (1) | WO2008029371A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288554B2 (en) * | 2006-09-08 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyridin-3-yl derivatives as immunomodulating agents |
MX2009002915A (es) | 2006-09-21 | 2009-03-31 | Actelion Pharmaceuticals Ltd | Derivados de fenilo y su uso como inmunomoduladores. |
WO2008076356A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
CA2695509A1 (en) * | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
KR20100092473A (ko) * | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
US20110028448A1 (en) * | 2008-03-06 | 2011-02-03 | Martin Bolli | Pyridine compounds |
WO2009109907A1 (en) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel pyrimidine-pyridine derivatives |
AU2009220893A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
MX2010009644A (es) * | 2008-03-07 | 2010-09-22 | Actelion Pharmaceuticals Ltd | Derivados piridin-2-ilo como agentes inmunomoduladores. |
CN104800208A (zh) | 2008-03-17 | 2015-07-29 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
TWI490214B (zh) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
JP2012515789A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | スフィンゴシン−1−リン酸アゴニストとしてのピラゾール−1,2,4−オキサジアゾール誘導体 |
JP2012515788A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置における、s1pアゴニストとしての置換オキサジアゾール誘導体 |
CN102361867A (zh) | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
JP5753104B2 (ja) * | 2009-03-03 | 2015-07-22 | メルク セローノ ソシエテ アノニム | S1p1レセプターアゴニストとして有用なオキサゾールピリジン誘導体 |
JP5569699B2 (ja) * | 2009-04-17 | 2014-08-13 | 石原産業株式会社 | 2−ハロゲノ−6位置換−4−トリフルオロメチルピリジンの製造方法 |
DE102009002514A1 (de) * | 2009-04-21 | 2010-10-28 | Evonik Degussa Gmbh | Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden |
PL2454255T3 (pl) * | 2009-07-16 | 2014-04-30 | Idorsia Pharmaceuticals Ltd | Pochodne pirydyn-4-ylowe jako agoniści S1P1/EDG1 |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
WO2011094008A1 (en) | 2010-01-27 | 2011-08-04 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
ES2539256T3 (es) | 2010-07-20 | 2015-06-29 | Bristol-Myers Squibb Company | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos |
JP5869579B2 (ja) | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換オキサジアゾール化合物およびそれらのs1p1アゴニストとしての使用 |
US9133179B2 (en) * | 2011-01-19 | 2015-09-15 | Actelion Pharmaceuticals Ltd. | 2-methoxy-pyridin-4-yl-derivatives |
PL2885266T3 (pl) | 2012-08-17 | 2020-11-16 | Actelion Pharmaceuticals Ltd | Sposób otrzymywania (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroksypropoksy)benzylideno)-2-(propyloimino)-3-(o-tolilo)tiazolidyn-4-onu i produktu pośredniego stosowanego w tym sposobie |
CA2900910C (en) * | 2013-03-15 | 2021-03-30 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
BR112017024785B1 (pt) * | 2015-05-20 | 2022-05-17 | Idorsia Pharmaceuticals Ltd | Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
WO2017004608A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
WO2017004610A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
WO2017004609A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
JP2020507611A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 原発性胆汁性胆管炎の治療のための化合物および方法 |
CN107311994A (zh) * | 2017-08-14 | 2017-11-03 | 淄博职业学院 | 一种s1p‑1受体激动剂药物分子的新型合成方法 |
CA3079833A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
CN109956912B (zh) * | 2017-12-26 | 2021-10-22 | 中国医学科学院药物研究所 | 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途 |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31990A (en) * | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
CA2051494C (en) | 1990-09-20 | 2006-03-14 | Robert J. Dinerstein | 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors |
DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
JP2002505868A (ja) | 1998-03-09 | 2002-02-26 | スミスクライン・ビーチャム・コーポレイション | ヒトEDG−1cポリヌクレオチドおよびポリペプチドおよびその使用法 |
DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
SK2512002A3 (en) | 1999-08-19 | 2002-07-02 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
PL369598A1 (en) | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
CA2472713C (en) | 2002-01-18 | 2011-07-19 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
DE60329073D1 (de) | 2002-01-18 | 2009-10-15 | Merck & Co Inc | Edg-rezeptoragonisten |
US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
AU2003276043A1 (en) | 2002-06-17 | 2003-12-31 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
DE10237883A1 (de) * | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
WO2004103279A2 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
TW200505416A (en) | 2003-08-12 | 2005-02-16 | Mitsubishi Pharma Corp | Bi-aryl compound having immunosuppressive activity |
RU2390519C2 (ru) * | 2003-08-29 | 2010-05-27 | Оно Фармасьютикал Ко., Лтд. | Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение |
JP2007528872A (ja) | 2003-10-01 | 2007-10-18 | メルク エンド カムパニー インコーポレーテッド | S1p受容体アゴニストとしての3,5−アリール置換、ヘテロアリール置換またはシクロアルキル置換された1,2,4−オキサジアゾール化合物 |
EP1697333A4 (en) * | 2003-12-17 | 2009-07-08 | Merck & Co Inc | 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG) |
CA2568766A1 (en) | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Crth2 receptor ligands for medicinal uses |
WO2006010379A1 (en) * | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
EP1826197B1 (en) * | 2004-12-13 | 2012-01-18 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
AU2006226018B2 (en) * | 2005-03-23 | 2012-07-12 | Idorsia Pharmaceuticals Ltd | Hydrogenated benzo (C) thiophene derivatives as immunomodulators |
JP5063581B2 (ja) * | 2005-03-23 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規チオフェン誘導体 |
US7605269B2 (en) | 2005-03-23 | 2009-10-20 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists |
RU2007140903A (ru) * | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
NZ563522A (en) | 2005-04-22 | 2010-01-29 | Daiichi Sankyo Co Ltd | Heterocyclic compound with immunosuppressive activity |
ATE477253T1 (de) | 2005-04-26 | 2010-08-15 | Neurosearch As | Neuartige oxadiazol-derivate und deren medizinische verwendung |
JP2008545767A (ja) * | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
US20070043104A1 (en) * | 2005-06-10 | 2007-02-22 | Luthman Ingrid K | UII-modulating compounds and their use |
MX2007016505A (es) * | 2005-06-24 | 2008-03-07 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno. |
JP2008546836A (ja) | 2005-06-28 | 2008-12-25 | アストラゼネカ アクチボラグ | 新規な用途 |
AR057894A1 (es) * | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
CA2635124C (en) * | 2006-01-24 | 2014-04-29 | Actelion Pharmaceuticals Ltd | Novel pyridine derivatives |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
WO2007098474A1 (en) | 2006-02-21 | 2007-08-30 | University Of Virginia Patent Foundation | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists |
JP4383525B2 (ja) * | 2006-05-09 | 2009-12-16 | ファイザー・プロダクツ・インク | シクロアルキルアミノ酸誘導体およびその医薬組成物 |
TWI408139B (zh) * | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
US8288554B2 (en) * | 2006-09-08 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyridin-3-yl derivatives as immunomodulating agents |
MX2009002915A (es) | 2006-09-21 | 2009-03-31 | Actelion Pharmaceuticals Ltd | Derivados de fenilo y su uso como inmunomoduladores. |
BRPI0717656A2 (pt) | 2006-09-29 | 2014-04-29 | Novartis Ag | Derivados de diaril oxadiazol |
JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
US20080138955A1 (en) * | 2006-12-12 | 2008-06-12 | Zhiyuan Ye | Formation of epitaxial layer containing silicon |
WO2008076356A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
CA2695509A1 (en) * | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
KR20100092473A (ko) * | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
BRPI0820868A2 (pt) * | 2007-12-10 | 2019-09-24 | Actelion Pharmaceuticals Ltd | composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado |
US20110028448A1 (en) * | 2008-03-06 | 2011-02-03 | Martin Bolli | Pyridine compounds |
WO2009109907A1 (en) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel pyrimidine-pyridine derivatives |
AU2009220893A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
MX2010009644A (es) * | 2008-03-07 | 2010-09-22 | Actelion Pharmaceuticals Ltd | Derivados piridin-2-ilo como agentes inmunomoduladores. |
DK2291080T3 (en) | 2008-05-14 | 2015-12-07 | Scripps Research Inst | Novel modulator of sphingosinphosphatreceptorer |
PL2454255T3 (pl) | 2009-07-16 | 2014-04-30 | Idorsia Pharmaceuticals Ltd | Pochodne pirydyn-4-ylowe jako agoniści S1P1/EDG1 |
-
2007
- 2007-09-06 CL CL200702593A patent/CL2007002593A1/es unknown
- 2007-09-06 PT PT78262870T patent/PT2069336E/pt unknown
- 2007-09-06 EP EP07826287A patent/EP2069336B1/en active Active
- 2007-09-06 RU RU2009112538/04A patent/RU2447071C2/ru active
- 2007-09-06 US US12/310,801 patent/US8580824B2/en active Active
- 2007-09-06 PL PL07826287T patent/PL2069336T3/pl unknown
- 2007-09-06 AR ARP070103940A patent/AR062683A1/es active IP Right Grant
- 2007-09-06 JP JP2009527264A patent/JP5253401B2/ja active Active
- 2007-09-06 DK DK07826287.0T patent/DK2069336T3/da active
- 2007-09-06 MX MX2009002233A patent/MX2009002233A/es active IP Right Grant
- 2007-09-06 BR BRPI0716171A patent/BRPI0716171B8/pt active IP Right Grant
- 2007-09-06 CA CA2661105A patent/CA2661105C/en active Active
- 2007-09-06 TW TW096133280A patent/TWI392671B/zh active
- 2007-09-06 NZ NZ576060A patent/NZ576060A/en unknown
- 2007-09-06 AU AU2007292993A patent/AU2007292993B2/en not_active Ceased
- 2007-09-06 CN CN200780033152XA patent/CN101511827B/zh active Active
- 2007-09-06 KR KR1020097006862A patent/KR101470659B1/ko active IP Right Grant
- 2007-09-06 MY MYPI20090912A patent/MY149853A/en unknown
- 2007-09-06 SI SI200731169T patent/SI2069336T1/sl unknown
- 2007-09-06 ES ES07826287T patent/ES2400533T3/es active Active
- 2007-09-06 WO PCT/IB2007/053594 patent/WO2008029371A1/en active Application Filing
-
2009
- 2009-03-04 IL IL197393A patent/IL197393A/en active IP Right Grant
- 2009-03-18 MA MA31729A patent/MA30718B1/fr unknown
- 2009-04-06 NO NO20091394A patent/NO342156B1/no unknown
-
2010
- 2010-02-11 HK HK10101596.4A patent/HK1133654A1/xx not_active IP Right Cessation
-
2013
- 2013-02-27 CY CY20131100186T patent/CY1113727T1/el unknown
- 2013-03-04 HR HRP20130181TT patent/HRP20130181T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1133654A1 (en) | Pyridin-4-yl derivatives as immunomodulating agents | |
HK1135976A1 (en) | Pyridin-3-yl derivatives as immunomodulating agents | |
PL2094263T3 (pl) | Pochodne 2-adamantylo-butyroamidowe jako selektywne inhibitory 11beta-HSD1 | |
IL194367A0 (en) | Dihydropyrazolopyrimidinone derivatives | |
HK1134284A1 (en) | Pyridizinone derivatives pyridizinone | |
IL193641A0 (en) | Spiroindolinone derivatives | |
IL195013A0 (en) | Pyridopyrimidinone derivatives | |
EP1973405A4 (en) | HYDROXYALKYMARYLAMIDE DERIVATIVES | |
IL198319A0 (en) | Spiroindolinone derivatives | |
ZA200806809B (en) | Pyridine-2-carboxamide derivatives | |
IL195422A0 (en) | 2-pyrazinecarboxamide derivatives | |
IL192401A0 (en) | Indol-3-yl-carbonyl-spiro-piperidine derivatives | |
ZA200809800B (en) | 2-Thioxanthine derivatives acting as Mpo-inhibitors | |
IL196364A0 (en) | Aminoindazolylurea derivatives | |
IL198059A0 (en) | 2-aminocarbonyl-pyridine derivatives | |
HRP20130641T1 (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
HK1136276A1 (en) | 5-hydroxymethyl-oxazolidin-2-one derivatives 5---2- | |
IL193211A0 (en) | Indazole-heteroaryl derivatives | |
IL197152A0 (en) | 5-phenyl-nicotinamide derivatives | |
EP2043633A4 (en) | THIADIAZOLIDINONDERIVATE | |
IL197239A0 (en) | Phenyloxyaniline derivatives | |
GB0614154D0 (en) | Novel Pyriazine Derivatives | |
IL194873A0 (en) | Methods for reducing 7/9-nitrotetracycline derivatives | |
GB0610018D0 (en) | Benzotriazepinone derivatives | |
GB0610019D0 (en) | Benzotriazepinone derivatives |